INTRODUCTION
============

Obesity is a growing medical problem in Korea ([@b22-jer-11-5-282]; [@b24-jer-11-5-282]; [@b27-jer-11-5-282]). Obesity has been known to relate to many other diseases or bad conditions, such as cancer ([@b12-jer-11-5-282]), stress ([@b24-jer-11-5-282]), heavy alcohol drinking ([@b18-jer-11-5-282]), and metabolic syndrome, which causes heart diseases ([@b3-jer-11-5-282]).

Many factors may affect the development of obesity, however, obesity shows complex relations of genetic and environmental factors ([@b1-jer-11-5-282]; [@b7-jer-11-5-282]; [@b10-jer-11-5-282]; [@b15-jer-11-5-282]). Many researchers have reported that various cytokines may influence the cellular signals affected by obesity ([@b19-jer-11-5-282]; [@b36-jer-11-5-282]), among them, insulin-like growth factors (IGFs) are major axis linked to insulin and growth hormone (GH) ([@b6-jer-11-5-282]; [@b32-jer-11-5-282]). They are major hormones affecting free fatty acid, plasma glucose, and adipose tissue, and that may show modified profiles in obesity ([@b26-jer-11-5-282]). Additionally, IGF1 is released in liver by stimulation of GH, and IGF1 receptor signal may also affect insulin signal ([@b9-jer-11-5-282]), however, nutrition, exercise, stress, and body mass index (BMI) may affect the IGF and GH levels ([@b8-jer-11-5-282]; [@b11-jer-11-5-282]; [@b13-jer-11-5-282]; [@b33-jer-11-5-282]; [@b35-jer-11-5-282]). Peet et al. reported IGF1 may be associated with beta-cell autoimmunity ([@b28-jer-11-5-282]), and Salmon et al. reported that IGF1 level may be associated with obesity resistance ([@b31-jer-11-5-282]).

Above mentioned studies suggest that IGF may affect or be affected by obesity. IGFs may affect cellular signals through its receptors, the IGF1 receptor (IGF1R) and IGF2 receptor (IGF2R) ([@b16-jer-11-5-282]; [@b38-jer-11-5-282]). IGF receptors have genetic variations that can affect various features in humans, such as cause the SHORT syndrome ([@b29-jer-11-5-282]), growth restriction ([@b2-jer-11-5-282]), and cancer responses to the receptor antibody therapies ([@b4-jer-11-5-282]; [@b23-jer-11-5-282]). However, there was no study directly reported on whether or not obesity and *IGF1R* gene or *IGF2R* gene is associated. Therefore, the relationship between obesity and the single nucleotide polymorphisms (SNPs) of *IGF1R* gene and *IGF2R* gene were investigated in this study.

MATERIALS AND METHODS
=====================

Study subjects
--------------

In the present study, a total of 243 subjects were analyzed ([Table 1](#t1-jer-11-5-282){ref-type="table"}). These subjects were recruited among participants that examined a general health check-up program. Subjects with severe diseases such as stroke, psychiatric disorders, and cancers were excluded. The biochemical characteristics of individuals were measured such as fasting plasma glucose, fasted glycated hemoglobin (HbA1c), total cholesterol (TC), high-density lipoprotein cholesterol (HDL-C), and low-density lipoprotein cholesterol (LDL-C). Body mass index (BMI) is calculated as weight (in kilograms) divided by the square of height (in meters). According to the classification of Korean Society for the Study of Obesity (underweight, BMI\<18; normal, BMI 18 to \<23; moderately obese, BMI 23 to \<25; obesity I, BMI 25 to \<30; obesity II, BMI≥30), subjects were divided into two subgroups, the abnormal (overweight/obese) group (BMI≥23) and the normal group (18\<BMI\<23).

SNP selection and genotyping
----------------------------

Peripheral bloods of all subjects were collected in EDTA or heparin tube. Genomic DNAs were extracted by QIAamp^®^ DNA mini kit (QIAGEN, Valencia, CA, USA). We selected exonic rs3743262 (Thr766Thr) and rs2229765 (Glu1043Glu) SNPs of *IGF1R* gene ([@b5-jer-11-5-282]) and rs629849 (Gly1619Arg) and rs1805075 (Asn2020Ser) SNPs of *IGF2R* gene. Genotype of each SNP was performed by direct sequencing (MACROGEN, Seoul, Korea).

Polymerase chain reaction (PCR) was employed using the specific primers. Conditions of PCR were 35 cycles at 94°C for 30 sec, 58°C for 30 sec, and 72°C for 30 sec, and 1 cycle at 72°C for 5 min for the final extension reaction. SeqManII software (DNASTAR, Madison, WI, USA) was used to determine the genotype.

Statistical analysis
--------------------

SNPStats (<http://bioinfo.iconcologia.net/index.php>) and SPSS 18.0 (SPSS Inc., Chicago, IL, USA) were used to determine the odds ratio (OR), 95% confidence interval (CI), and *P*-value. Multiple logistic regression models (codominant1, codominant2, dominant, recessive, and log-additive models) were applied and age and gender as covariables were adjusted. When the numbers of subject were below 5, the *P*-values were recalculated by Fisher's exact test. The *P*-value below 0.05 was considered significant.

RESULTS
=======

In the control group, the genotype distributions for all SNPs were in HWE \[rs3743262 (*P*=0.33) and rs2229765 (*P*=0.45) SNPs of *IGF1R* gene and rs629849 (*P*=1.00) and rs1805075 (*P*=0.84) SNPs of *IGF2R* gene\]. The genotype frequencies of the polymorphisms were compared between the control group and the overweight/obese group by using logistic regression models with adjustment for age and gender. The genotype distributions of rs3743262 and rs2229765 SNPs of *IGF1R* gene and rs629849 and rs1805075 SNPs of *IGF2R* gene in each group were shown in [Table 2](#t2-jer-11-5-282){ref-type="table"}. Among tested SNPs in *IGF1R* and *IGF2R* genes, rs629849 SNP of *IGF2R* gene showed significant association with obesity \[OR=1.86, 95% CI=1.02--3.40, *P*=0.044 in codominant1 model (G/G genotype versus G/A genotype); OR=1.99, 95% CI=1.10--3.57, *P*=0.020 in dominant model (G/G genotype versus G/A genotype+A/A genotype); OR=1.93, 95% CI=1.13--3.31, *P*=0.013 in log-additive model (G/G genotype versus G/A genotype versus A/A genotype)\], respectively. And allele distribution between the control group and overweight/obese group also showed significant difference (OR=1.93, 95% CI=1.14--3.28, *P*=0.015). However, three SNPs did show any significant association with development of obesity.

In haplotype analysis, we analyzed haplotype using Haploview 4.2. There were four haplotypes (CG, TA, CA, and TG haplotype) in *IGF1R* gene and three haplotypes (GA, GG, and AA haplotype) in *IGF2R* gene. Among haplotypes, AA haplotype in *IGF2R* gene showed significant difference between the control group and the overweight/obese group (*P*=0.0138) ([Table 3](#t3-jer-11-5-282){ref-type="table"}).

DISCUSSION
==========

In the present study result, the two SNPs (rs3743262 and rs2229765) in *IGF1R* gene did not show any relationship with obesity, also, a SNP (rs1805075) in *IGF2R* gene did not showed any relationship. However, only one SNP (rs629849) of *IGF2R* gene was associated with obesity. Minor allele frequency (MAF) of rs629849 in our study was 0.1 in the control group. MAF of rs629849 in NCBI dbSNP (<http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs=629849>) was 0.0968. Therefore MAF in the control group is consistent with MAF in NCBI dbSNP. Significant associations are shown in the allele frequency, co-dominant model, dominant model, and log-additive model, respectively. In all of them, ORs were positive in the minor allele (A). Therefore, it suggests that the minor allele "A" of the rs629849 in the *IGF2R* gene may be associated with development of obesity.

IGF2R is a multifunctional receptor that possesses binding sites for diverse ligands, including IGF2, retinoic acid, TGF-beta (TGFB1), urokinase-type plasminogen activator receptor (UPAR), and mannose-6-phosphate (M6P) ([@b17-jer-11-5-282]). Additionally, IGF2R is involved in lysozyme reaction and cytotoxic T cell apoptosis ([@b20-jer-11-5-282]; [@b25-jer-11-5-282]). Which means IGF2R may have wide range of signal transduction, however, Le Stunff et al. reported that increased expression of mutated insulin(INS) and *IGF2* gene may predispose offspring to postnatal fat deposition ([@b21-jer-11-5-282]). And Rodriguez et al. reported that certain haplotype composed by the gene region of IGF2-INS-thyroid hormone (TH) is related with obesity ([@b30-jer-11-5-282]). Also, IGF2-INS region is associated with past famine history in individuals ([@b34-jer-11-5-282]). Interestingly, IGF2R has degradation function of IGF2, which is known as mitogen ([@b37-jer-11-5-282]). Rezgui, studied the correlation of "A" allele and receptor function, however, the researchers concluded that it showed no direct effect and they suspected the linkage between other intronic polymorphisms.

In previous study, rs629849 of *IGF2R* gene was significantly associated with higher level of circulating IGF2 level in "A" allele homozygote woman ([@b14-jer-11-5-282]). The authors concluded that "A" homozygote in rs629849 of *IGF2R* gene may modulate IGF2 level in sex-specific manner, and it may affect colorectal cancer risk as a mitogen effect of IGF2. Additionally, rs629849 of IGF2R gene was associated with advanced stage of oral cancer, that "GG "genotype showed ORs of 0.32 compared to "A" allele carriers ([@b37-jer-11-5-282]). The previous research results are, consistent with ours that the minor "A" allele may tribute to the obesity development.

In conclusion, though it was marginal relation in this study, we suggest that having "A" allele of rs629849 of *IGF2R* gene may be associated with development of obesity in the Korean population.
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###### 

Clinical data of subjects included in the study

  Clinical indicator               Overweight/obesity (n=120)   Control (n=123)
  -------------------------------- ---------------------------- -----------------
  Age (yr)                         43.3±14.2                    35.3±11.3
  Male/Female                      87/33                        45/78
  Fasting plasma glucose (mg/dL)   90.9±22.0                    85.3±6.6
  HbA1c (%)                        5.8±0.7                      5.5±0.5
  Total cholesterol (mg/dL)        190.7±33.0                   171.0±26.4
  HDL-C (mg/dL)                    49.6±10.7                    54.9±11.8
  LDL-C (mg/dL)                    288.2±53.6                   261.4±45.7

HbA1c, Fasted glycated hemoglobin; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol.

###### 

Genetic analysis of exonic polymorphisms in *IGF1R* and *IGF2R* genes between overweight/obesity and control subjects

  SNPs         Genotype Allele   Control      Overweight/obese   Models         OR (95% CI)          *P*     Fisher' exact *P*
  ------------ ----------------- ------------ ------------------ -------------- -------------------- ------- -------------------
  *IGF1R*      C/C               50 (40.6)    51 (42.5)          Codominant1    0.93 (0.55--1.58)    0.80    
  rs3743262    C/T               61 (49.6)    58 (48.3)          Codominant2    0.90 (0.36--2.22)    0.82    
  Thr766Thr    T/T               12 (9.8)     11 (9.2)           Dominant       0.93 (0.56--1.54)    0.77    
                                                                 Recessive      0.93 (0.40--2.21)    0.88    
                                                                 Log-additive   0.94 (0.63--1.40)    0.77    
               C                 161 (65.4)   160 (66.7)                        1                            
               T                 85 (34.6)    80 (33.3)                         0.95 (0.65--1.38)    0.78    
                                                                                                             
  *IGF1R*      G/G               48 (39)      44 (36.7)          Codominant1    1.06 (0.62--1.81)    0.84    
  rs2229765    G/A               66 (53.7)    64 (53.3)          Codominant2    1.45 (0.56--3.78)    0.44    
  Glu1043Glu   A/A               9 (7.3)      12 (10.0)          Dominant       1.11 (0.66--1.86)    0.70    
                                                                 Recessive      1.41 (0.57--3.47)    0.46    
                                                                 Log-additive   1.14 (0.76--1.72)    0.52    
               G                 162 (65.9)   152 (63.3)                        1                            
               A                 84 (34.1)    88 (36.7)                         1.12 (0.77--1.62)    0.56    
                                                                                                             
  *IGF2R*      G/G               99 (80.5)    81 (67.5)          Codominant1    1.86 (1.02--3.40)    0.044   
  rs629849     G/A               23 (18.7)    35 (29.2)          Codominant2    4.89 (0.54--44.61)   0.16    0.18
  Gly1619Arg   A/A               1 (0.8)      4 (3.3)            Dominant       1.99 (1.10--3.57)    0.020   
                                                                 Recessive      4.21 (0.46--38.16)   0.15    0.21
                                                                 Log-additive   1.93 (1.13--3.31)    0.013   
               G                 221 (89.8)   197 (82.1)                        1                            
               A                 25 (10.2)    43 (17.9)                         1.93 (1.14--3.28)    0.015   
                                                                                                             
  *IGF2R*      A/A               52 (42.3)    57 (47.5)          Codominant1    0.75 (0.44--1.29)    0.30    
  rs1805075    A/G               57 (46.3)    47 (39.2)          Codominant2    1.04 (0.46--2.34)    0.92    
  Asn2020Ser   G/G               14 (11.4)    16 (13.3)          Dominant       0.81 (0.49--1.34)    0.41    
                                                                 Recessive      1.20 (0.56--2.58)    0.64    
                                                                 Log-additive   0.93 (0.64--1.35)    0.71    
               A                 161 (65.4)   161 (67.1)                        1                            
               G                 85 (34.6)    79 (32.9)                         0.93 (0.64--1.35)    0.70    

SNP, Single nucleotide polymorphism; OR, odds ratio; CI, confidence interval.

###### 

Haplotype analysis of exonic polymorphisms in *IGF1R* and *IGF2R* genes between overweight/obesity and control subjects

  Gene      Haplotype   Frequency   Control   Overweight/obese   Chi Square   *P*             
  --------- ----------- ----------- --------- ------------------ ------------ ------- ------- --------
  *IGF1R*   CG          0.535       133.8     112.2              126.1        113.9   0.166   0.68
            TA          0.228       56.8      189.2              54.1         185.9   0.02    0.89
            CA          0.126       27.2      218.8              33.9         206.1   1.037   0.31
            TG          0.111       28.2      217.8              25.9         214.1   0.056   0.81
                                                                                              
  *IGF2R*   GA          0.523       136       110                118          122     1.822   0.18
            GG          0.337       85        161                79           161     0.145   0.70
            AA          0.14        25        221                43           197     6.07    0.0138

IGF1R, Insulin-like growth factor 1 receptor; IGF2R, insulin-like growth factor 2 receptor.
